Apcelleera shares surge up to 41% on mid-stage trial results for facial-flushing treatment

ABCL AbCellera Biologics Inc

$12.55 +4.37%

View chart & analysis →

1. 1Apcelleera Biologics (ABCL) jumped as much as 41% after announcing mid-stage clinical results for its facial-flushing treatment candidate.
2. 2In a 4-week trial of 92 postmenopausal women, the injectable candidate reduced the frequency and severity of symptoms versus placebo, with no serious adverse events.
3. 3Market capitalization reached nearly $3 billion, and the CEO highlighted its potential as a blockbuster non-hormonal therapy.

Source Bloomberg · View original ↗

Today's 5 AI picks, all free

Nothing hidden: past picks and how they did against the S&P 500.

See today's picks →